The following parameters were identified by the review:
the sensitivity of ELISA was 92.7% and the specificity was 100%;
the sensitivity of PCR was 100% and the specificity was 100%;
the proportion of people with mild disease was 46%;
the proportion of people with moderate disease was 43%;
the proportion of people with severe disease was 11%;
the underlying prevalence of HCV was 32%;
the proportion of people who accept an ELISA test was 49%;
the proportion of people who accept an ELISA test who also accept a PCR test was 100%;
the proportion of people with positive ELISA and PCR tests who accept liver biopsy was 77%;
the proportion of people with moderate disease that accept treatment was 50%;
complications arising from liver biopsy were 0.3%;
complications arising from liver biopsy that required hospital admission were 7%;
the proportion of liver biopsy complications resulting in death was 0.03%;
progression from cirrhosis to ascites, variceal bleeds and hepatic encephalopathy was 1.6%;
progression from cirrhosis to hepatic carcinoma was 1.4%;
the annual death rate following diagnosis of hepatic carcinoma was 80%; and
adherence to treatment was 100%.